San Francisco, CA, September 7 -- Elsevier, the leading publisher of
scientific, technical and medical information products and services, today
announced the launch of OncologySTAT,
a free website featuring high-quality, scientifically-based oncology and
cancer care information and education. The site is aimed at more than 1
million US oncologists, hematologists, oncology nurses, and all other
healthcare professionals involved in the treatment, care and diagnosis of
patients with cancer. OncologySTAT is advertiser supported and the first
online community of its kind launched by a scholarly publisher.
OncologySTAT offers multiple professional cancer information resources in a
single online location. Healthcare professionals who register with the site
can search and download current peer-reviewed articles from more than 100
Elsevier cancer related journals. Clinicians can stay up to date and build
expertise leading to improved patient care and enhanced practice management
through features such as journal and MEDLINE search, professional drug and
interaction databases, news, blogs and webinars. OncologySTAT also provides
cancer patients, survivors and caregivers with access to the same information
used by experienced cancer care professionals.
“OncologySTAT offers resources to improve cancer diagnosis, treatment, and
prevention in one source at no cost to clinicians,” says Lee S. Schwartzberg,
M.D., F.A.C.P., physician and head of research, The West Clinic, OncologySTAT
Advisory Board Co-Chairman and Editor-in-Chief. “No other online destination
offers such a breadth of integrated scientifically-based cancer research,
information and education for free.”
Meeting an Identified Need
Oncology is the second largest and
fastest growing therapy class in the world. Cancer professionals are
challenged by the multitude of information sources available, and by the
frequency in which new information is published.
“Oncologists who are classified as heavy online users may visit cancer-related
websites four to five times per day to access the latest scientific
information,” says Axel Grothey M.D., OncologySTAT Advisory Board Member and
Associate Editor. “Oncologists research the web more often than any clinical
specialty because there are more than 500 cancer drugs in the pipeline.
Clinicians want to know when these drugs will become available and how
patients may tolerate various drug combinations.”
OncologySTAT’s professional information features include the following:
• Peer-reviewed Journal Articles: registered users can search and
access current journal articles from over 100 Elsevier cancer related journals
including The Lancet Oncology, The Breast, Lung Cancer, Cancer Letters, The
American Journal of Medicine, Seminars in Oncology, Seminars in Radiation
Oncology, Seminars in Hematology, Blood Reviews, etc.
• Journal Scans: Weekly professional summaries of the most
important scientific research from 25 leading cancer journals, including
Journal of Clinical Oncology, Journal of the National Cancer Institute, CA: A
Cancer Journal for Clinicians, Blood, JAMA, and New England Journal of
Medicine.
• Cancer News Feeds: Late-breaking regulatory and drug approval
updates from the widely respected Pink Sheet, as well as professional medical
and conference news from the International Medical News Group and MDConsult.
• InfoBlast E-Newsletter: A weekly e-newsletter
highlighting key oncology news, research and site content features.
• Integrated MEDLINE Search: Immediate access to search
MEDLINE’s vast repository of scientific abstracts without exiting OncologySTAT.
• Cancer-type “Spotlights”: 27 cancer type
“Spotlight” sections featuring news, journals, article scans, clinical texts
summaries, patient handouts and webinars on cancers such as bone, breast,
prostate and lung.
• Chemotherapy Regimens: Guidelines and protocols from the
Elsevier Guide to Oncology Drugs and Regimens (2006) obtained through searches
by drug or cancer type.
• Professional Drug Monograph and Interactions Database: Powered
by Gold Standard.
“OncologySTAT is a first for getting a broad range of the latest
evidence-based oncology information and news into the hands of health
professionals in a manner that fits the practitioner’s workflow and
time-constraints, so they can spend more time treating patients,” said Brian
Nairn, CEO, Elsevier Health Sciences. “OncologySTAT matches the user’s need
for rapid integrated access to the latest trusted oncology information with
the pharmaceutical industry’s growing need and desire to communicate directly
with oncology practitioners via credible online channels.”
The site operates independently from any particular professional society or
sponsor. However, the site offers multiple marketing and promotional
opportunities, including targeted advertising and sponsorship of specific site
sections or content types.
The OncologySTAT advisory board includes 10 of the most influential names in
oncology, including four past-presidents of the American Society of Clinical
Oncology (ASCO). The editorial team includes Lee Schwartzberg M.D., F.A.C.P,
OncologySTAT Editor in Chief, Axel Grothey, M.D., Associate Editor, and a team
of seasoned professional medical writers and oncology fellows.
###
About Elsevier
Elsevier is a world-leading publisher of
scientific, technical and medical information products and services. Working
in partnership with the global science and health communities, Elsevier’s
7,000 employees in over 70 offices worldwide publish more than 2,000 journals
and 1,900 new books per year, in addition to offering a suite of innovative
electronic products, such as ScienceDirect,
MDConsult, Scopus,
bibliographic databases, and online reference works.
Elsevier is a global business
headquartered in Amsterdam, The Netherlands and has offices worldwide.
Elsevier is part of Reed Elsevier Group
plc, a world-leading publisher and information provider. Operating in the
science and medical, legal, education and business-to-business sectors, Reed
Elsevier provides high-quality and flexible information solutions to users,
with increasing emphasis on the Internet as a means of delivery. Reed
Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock
Exchange), RUK and ENL (New York Stock Exchange).
Media Contact:
Tom Reller
+1 212.462.1912
T.Reller@Elsevier.com
